WHO 2013 guidelines: what about the missing formulations?
25 July 2013. Related: Conference reports, Treatment access, Paediatric care, Guidelines.
2013
WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500
25 July 2013. Related: Conference reports, Guidelines.
Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects
25 July 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir update: drug resistance in people who are treatment-naive and -experienced
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013
25 July 2013. Related: Conference reports, Antiretrovirals.
Non-standard combinations: NRTI-sparing combinations
25 July 2013. Related: Conference reports, Antiretrovirals.
ARVs and bone health: the role of NRTIs in second-line therapy
25 July 2013. Related: Conference reports, Side effects.
No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors
25 July 2013. Related: Conference reports, Cure-related research, Basic science and immunology.
HIV cure research: further capsules at IAS 2013
25 July 2013. Related: Conference reports, Cure-related research, Basic science and immunology.
Partner-dependent immune differences may protect against HIV infection
25 July 2013. Related: Conference reports, HIV prevention and transmission.
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
25 July 2013. Related: Conference reports, Treatment access, Hepatitis coinfection.
5th International Workshop on HIV Pediatrics, 28-29 June 2013, Kuala Lumpur
25 July 2013. Related: Conference reports.
Vertical transmission continues to decline in UK and Ireland
25 July 2013. Related: Conference reports, Pregnancy.
Decline in late preterm delivery with vaginal birth in Europe
25 July 2013. Related: Conference reports, Pregnancy.
High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Decreased growth in ART exposed uninfected infants in Botswana
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Antiretrovirals, doses and formulations for children
25 July 2013. Related: Conference reports, Antiretrovirals, Paediatric care.
International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 4-8 June 2013, Toronto
25 July 2013. Related: Conference reports.
Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
One in five people with recent HIV infection in Spain have X4/R5 mixed tropic virus
25 July 2013. Related: Conference reports, Virology.
Ending global use of d4T: UNITAID to tip market to safer alternatives
25 July 2013. Related: Treatment access, Side effects.
TRIPS extension for least developed countries
25 July 2013. Related: Treatment access.
Community request Gilead to study and develop separate formulation of new tenofovir prodrug
25 July 2013. Related: Antiretrovirals, Treatment access.
Sad news regarding attempt to duplicate the cure achieved in Timothy Brown
25 July 2013. Related: Basic science and immunology.
ART reduces HIV reservoirs in elite controllers: implications for cure research
25 July 2013. Related: Basic science and immunology.
Bangkok Tenofovir Study: US CDC recommends oral PrEP for injecting drug users – based on 16 fewer infections over 5 years
25 July 2013. Related: HIV prevention and transmission.
CROI website: vital community and research resource vanishes
25 July 2013. Related: Other news.
FDA guidance for industry HIV development and trials
25 July 2013. Related: Other news.
TAG report: Immune system, HIV, and ageing
25 July 2013. Related: On the web.
RITA! summer issue: HIV and cardiovascular disease
25 July 2013. Related: On the web.
HTB supplement: 2013 pipeline report
30 June 2013. Related: Editorial, Special reports, Pipeline report.
Dedication: Spencer Cox
30 June 2013. Related: Pipeline report.
Seven ways to speed up the pipeline
30 June 2013. Related: Pipeline report.
Executive summary and research policy recommendations
30 June 2013. Related: Pipeline report, Antiretrovirals, Treatment strategies, Diagnostics, Hepatitis coinfection, TB coinfection.
The antiretroviral pipeline 2013
30 June 2013. Related: Pipeline report, Antiretrovirals.
The paediatric antiretroviral pipeline
30 June 2013. Related: Pipeline report, Antiretrovirals, Paediatric care.
Retrofitting for purpose: treatment optimisation 2013
30 June 2013. Related: Pipeline report, Fit for purpose, Treatment strategies.
Preventive technologies, research toward a cure, and immune-based and gene therapies
30 June 2013. Related: Pipeline report, HIV prevention and transmission, Cure-related research.
Hepatitis C drug development catapults onward
30 June 2013. Related: Pipeline report, Hepatitis coinfection.
Low- and middle-income countries defuse hepatitis C
30 June 2013. Related: Pipeline report, Hepatitis coinfection, Virology.
The tuberculosis diagnostics pipeline
30 June 2013. Related: Pipeline report, Diagnostics, TB coinfection.
The tuberculosis treatment pipeline
30 June 2013. Related: Pipeline report, Treatment strategies, TB coinfection.
The tuberculosis vaccine pipeline
30 June 2013. Related: Pipeline report, TB coinfection, Vaccines and microbicides.
Acknowledgments
30 June 2013. Related: Pipeline report.
Volume 14 Number 5/6 May/June 2013
29 May 2013. Related: Editorial.
14th International Workshop on Clinical Pharmacology, 22-24 April 2013, Amsterdam
29 May 2013. Related: Conference reports.
Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above
29 May 2013. Related: Conference reports, Paediatric care, PK and drug interactions.
Bilirubin as a surrogate marker for atazanavir in children
29 May 2013. Related: Conference reports, Paediatric care, PK and drug interactions.
Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia
29 May 2013. Related: Conference reports, Pregnancy, PK and drug interactions.
Tenofovir population pharmacokinetics in pregnancy
29 May 2013. Related: Conference reports, Pregnancy, PK and drug interactions.
Effect of rifampicin on BMS-663068 in HIV negative volunteers
29 May 2013. Related: Conference reports, PK and drug interactions.
Coformulated darunavir/cobicistat: an alternative to separate ritonavir boosting
29 May 2013. Related: Conference reports, PK and drug interactions.
Continuous infusion of T-20 in multidrug resistant patient with intolerance of s.c. injections
29 May 2013. Related: Conference reports, PK and drug interactions.
20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta
29 May 2013. Related: Conference reports.
Small increase in birth defects in the French Perinatal Cohort
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Uptake and retention in Malawi’s Option B+ programme
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care
29 May 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Cardiovascular disease and other non-AIDS defining events
29 May 2013. Related: Conference reports, Coinfections and complications.
Dramatic advances at CROI for HCV treatment: telaprevir, boceprevir, faldaprevir, sofosbuvir, ABT-450, ABT-267, ABT-333 and ledipasvir
29 May 2013. Related: Conference reports, Hepatitis coinfection.
Basic research highlights from CROI 2013
29 May 2013. Related: Conference reports, Basic science and immunology.
Probiotic/prebiotic supplement combination shows benefits in SIV-infected pigtailed macaques
29 May 2013. Related: Conference reports, Basic science and immunology.
Upcoming WHO ART guidelines (2013)
29 May 2013. Related: Treatment access.
Fixed dose combination efavirenz/tenofovir/FTC for South Africa
29 May 2013. Related: Treatment access.